Cargando…
Au naturale: use of biologically derived cyclic di-nucleotides for cancer immunotherapy
Cyclic di-nucleotides (CDNs) are widespread second messenger signalling molecules that regulate fundamental biological processes across the tree of life. These molecules are also potent modulators of the immune system, inducing a Type I interferon response upon binding to the eukaryotic receptor STI...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Royal Society
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670957/ https://www.ncbi.nlm.nih.gov/pubmed/34905701 http://dx.doi.org/10.1098/rsob.210277 |
_version_ | 1784615065272451072 |
---|---|
author | Waters, Christopher M. |
author_facet | Waters, Christopher M. |
author_sort | Waters, Christopher M. |
collection | PubMed |
description | Cyclic di-nucleotides (CDNs) are widespread second messenger signalling molecules that regulate fundamental biological processes across the tree of life. These molecules are also potent modulators of the immune system, inducing a Type I interferon response upon binding to the eukaryotic receptor STING. Such a response in tumours induces potent immune anti-cancer responses and thus CDNs are being developed as a novel cancer immunotherapy. In this review, I will highlight the use, challenges and advantages of using naturally occurring CDNs to treat cancer. |
format | Online Article Text |
id | pubmed-8670957 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Royal Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-86709572021-12-28 Au naturale: use of biologically derived cyclic di-nucleotides for cancer immunotherapy Waters, Christopher M. Open Biol Review Cyclic di-nucleotides (CDNs) are widespread second messenger signalling molecules that regulate fundamental biological processes across the tree of life. These molecules are also potent modulators of the immune system, inducing a Type I interferon response upon binding to the eukaryotic receptor STING. Such a response in tumours induces potent immune anti-cancer responses and thus CDNs are being developed as a novel cancer immunotherapy. In this review, I will highlight the use, challenges and advantages of using naturally occurring CDNs to treat cancer. The Royal Society 2021-12-15 /pmc/articles/PMC8670957/ /pubmed/34905701 http://dx.doi.org/10.1098/rsob.210277 Text en © 2021 The Authors. https://creativecommons.org/licenses/by/4.0/Published by the Royal Society under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, provided the original author and source are credited. |
spellingShingle | Review Waters, Christopher M. Au naturale: use of biologically derived cyclic di-nucleotides for cancer immunotherapy |
title | Au naturale: use of biologically derived cyclic di-nucleotides for cancer immunotherapy |
title_full | Au naturale: use of biologically derived cyclic di-nucleotides for cancer immunotherapy |
title_fullStr | Au naturale: use of biologically derived cyclic di-nucleotides for cancer immunotherapy |
title_full_unstemmed | Au naturale: use of biologically derived cyclic di-nucleotides for cancer immunotherapy |
title_short | Au naturale: use of biologically derived cyclic di-nucleotides for cancer immunotherapy |
title_sort | au naturale: use of biologically derived cyclic di-nucleotides for cancer immunotherapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670957/ https://www.ncbi.nlm.nih.gov/pubmed/34905701 http://dx.doi.org/10.1098/rsob.210277 |
work_keys_str_mv | AT waterschristopherm aunaturaleuseofbiologicallyderivedcyclicdinucleotidesforcancerimmunotherapy |